Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Japan 2022 Review/Outlook: Supply Crisis, Incentives, Cost Controls In Focus

Balance Of Give And Take

Executive Summary

As Japan's pharma market continues to face supply chain challenges and rising healthcare costs, regulatory authorities are looking to policies that balance incentives in critical areas and temporary price rises with other other ongoing measures to contain the national drugs bill. The Pink Sheet takes a look at the key changes last year and what to expect in 2023.

You may also be interested in...



Third Time Lucky As Japan Finally Approves Shionogi’s Oral COVID Antiviral

Shionogi’s once-daily oral COVID-19 antiviral finally gets Japan approval after being considered for the third time by an expert panel, paving the way for public availability of the country’s first such home-grown option in early December.

PhRMA Promotes Cluster Concept In Japan Reform Wish List

US industry association promotes an exchanges with Japan on bioclusters, while continuing to push for holistic debate on reforms to the country’s national healthcare system and changes to reimbursement pricing it sees as supporting innovation.

Japan Again Postpones Approval Of Shionogi COVID Antiviral

Xocova’s emergency approval stymied by uncertainties over efficacy and other characteristics that could effectively limit its use, prompting decision to await Phase III data later this year.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS147486

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel